Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

Stock Analysis

HBIO Harvard Bioscience Inc

Price (delayed)

$0.315

Market cap

$13.88M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.28

Enterprise value

$53.11M

Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its customers range from renowned ...

Highlights

The EPS has grown by 15% from the previous quarter

The company's net income rose by 13% QoQ

Harvard Bioscience's debt has increased by 4.8% YoY but it has decreased by 2.8% from the previous quarter

HBIO's quick ratio has shrunk by 55% YoY and by 54% QoQ

The gross profit has declined by 17% year-on-year and by 4.1% since the previous quarter

Sector: Healthcare

Industry: Medical Instruments & Supplies

Website: http://www.harvardbioscience.com

Peers: BRKR A TMO JNJ

Key stats

What are the main financial stats of HBIO

Market

Shares outstanding

44.07M

Market cap

$13.88M

Enterprise value

$53.11M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

0.22

Price to sales (P/S)

0.15

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

0.56

Earnings

Revenue

$94.14M

Gross profit

$54.77M

Operating income

-$6.21M

Net income

-$12.41M

EBIT

-$8.46M

EBITDA

-$1.3M

Free cash flow

-$1.82M

Per share

EPS

-$0.28

EPS diluted

-$0.28

Free cash flow per share

-$0.04

Book value per share

$1.45

Revenue per share

$2.16

TBVPS

$1.36

Balance sheet

Total assets

$126.64M

Total liabilities

$63.3M

Debt

$43.34M

Equity

$63.34M

Working capital

-$9.84M

Liquidity

Debt to equity

0.68

Current ratio

0.82

Quick ratio

0.35

Net debt/EBITDA

-30.2

Margins

EBITDA margin

-1.4%

Gross margin

58.2%

Net margin

-13.2%

Operating margin

-6.6%

Efficiency

Return on assets

-9.5%

Return on equity

-18.7%

Return on invested capital

-12.6%

Return on capital employed

-11.8%

Return on sales

-9%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

HBIO stock price

How has the Harvard Bioscience stock price performed over time

Intraday

3.41%

1 week

-9.4%

1 month

-31.37%

1 year

-91.15%

YTD

-85.07%

QTD

-44.35%

Financial performance

How have Harvard Bioscience's revenue and profit performed over time

Revenue

$94.14M

Gross profit

$54.77M

Operating income

-$6.21M

Net income

-$12.41M

Gross margin

58.2%

Net margin

-13.2%

The gross profit has declined by 17% year-on-year and by 4.1% since the previous quarter

Harvard Bioscience's revenue has decreased by 16% YoY and by 3.7% from the previous quarter

The company's net income rose by 13% QoQ

Harvard Bioscience's net margin has increased by 10% from the previous quarter

Price vs fundamentals

How does HBIO's price correlate with its fundamentals

Growth

What is Harvard Bioscience's growth rate over time

Valuation

What is Harvard Bioscience stock price valuation

P/E

N/A

P/B

0.22

P/S

0.15

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

0.56

The EPS has grown by 15% from the previous quarter

HBIO's price to book (P/B) is 91% less than its 5-year quarterly average of 2.5 and 88% less than its last 4 quarters average of 1.9

The equity has declined by 13% year-on-year and by 3% since the previous quarter

The stock's price to sales (P/S) is 91% less than its 5-year quarterly average of 1.7 and 88% less than its last 4 quarters average of 1.3

Harvard Bioscience's revenue has decreased by 16% YoY and by 3.7% from the previous quarter

Efficiency

How efficient is Harvard Bioscience business performance

The ROS has grown by 13% from the previous quarter

The return on assets has increased by 11% since the previous quarter

The return on equity has grown by 10% since the previous quarter

HBIO's return on invested capital is up by 7% since the previous quarter

Dividends

What is HBIO's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for HBIO.

Financial health

How did Harvard Bioscience financials performed over time

The total assets is 100% more than the total liabilities

HBIO's current ratio has dropped by 60% since the previous quarter and by 56% year-on-year

HBIO's quick ratio has shrunk by 55% YoY and by 54% QoQ

Harvard Bioscience's debt is 32% less than its equity

The company's debt to equity rose by 19% YoY

The equity has declined by 13% year-on-year and by 3% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.